JP2023531511A5 - - Google Patents
Info
- Publication number
- JP2023531511A5 JP2023531511A5 JP2022579691A JP2022579691A JP2023531511A5 JP 2023531511 A5 JP2023531511 A5 JP 2023531511A5 JP 2022579691 A JP2022579691 A JP 2022579691A JP 2022579691 A JP2022579691 A JP 2022579691A JP 2023531511 A5 JP2023531511 A5 JP 2023531511A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- utr
- sequence number
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063042822P | 2020-06-23 | 2020-06-23 | |
| US63/042,822 | 2020-06-23 | ||
| US202163165094P | 2021-03-23 | 2021-03-23 | |
| US63/165,094 | 2021-03-23 | ||
| US202163165469P | 2021-03-24 | 2021-03-24 | |
| US63/165,469 | 2021-03-24 | ||
| PCT/US2021/038780 WO2021262909A2 (en) | 2020-06-23 | 2021-06-23 | Lnp compositions comprising mrna therapeutics with extended half-life |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023531511A JP2023531511A (ja) | 2023-07-24 |
| JP2023531511A5 true JP2023531511A5 (https=) | 2024-07-01 |
Family
ID=77155849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022579691A Pending JP2023531511A (ja) | 2020-06-23 | 2021-06-23 | 半減期が延長されたｍＲＮＡ治療薬を含むＬＮＰ組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230242908A1 (https=) |
| EP (1) | EP4168556A2 (https=) |
| JP (1) | JP2023531511A (https=) |
| KR (1) | KR20230042005A (https=) |
| CN (1) | CN116194151A (https=) |
| AU (1) | AU2021297248A1 (https=) |
| BR (1) | BR112022025991A2 (https=) |
| CA (1) | CA3187261A1 (https=) |
| IL (1) | IL299196A (https=) |
| MX (1) | MX2022016550A (https=) |
| WO (1) | WO2021262909A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250313830A1 (en) * | 2022-03-25 | 2025-10-09 | Modernatx, Inc. | Messenger ribonucleic acids with extended half-life |
| US20250221931A1 (en) * | 2022-03-25 | 2025-07-10 | Modernatx, Inc. | Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia |
| WO2023196399A1 (en) * | 2022-04-06 | 2023-10-12 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria |
| WO2023215498A2 (en) * | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
| KR20250047488A (ko) * | 2023-09-27 | 2025-04-04 | 한미약품 주식회사 | 변형된 폴리아데닐 서열을 포함하는 핵산 분자 |
| KR20250047490A (ko) * | 2023-09-27 | 2025-04-04 | 한미약품 주식회사 | 변형된 폴리아데닐 서열 및 ox40l 단백질 코딩서열을 포함하는 핵산 분자 |
| KR20250047489A (ko) * | 2023-09-27 | 2025-04-04 | 한미약품 주식회사 | 변형된 폴리아데닐 서열 및 p53 단백질 코딩서열을 포함하는 핵산 분자 |
| CN117603029B (zh) * | 2023-11-21 | 2025-12-19 | 江苏禾本生化有限公司 | 一种戊菌唑关键中间体的合成方法 |
| WO2025255199A1 (en) * | 2024-06-05 | 2025-12-11 | Modernatx, Inc. | Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof |
| WO2026085234A1 (en) * | 2024-10-18 | 2026-04-23 | Modernatx, Inc. | 3' untranslated region sequences for extending messenger ribonucleic acids half-life |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8613481D0 (en) | 1986-06-04 | 1986-07-09 | Diatech Ltd | Translation of mrna |
| GB2284210B (en) | 1993-11-26 | 1997-11-12 | British Tech Group | Translational enhancer DNA from a kinesin gene |
| US5824497A (en) | 1995-02-10 | 1998-10-20 | Mcmaster University | High efficiency translation of mRNA molecules |
| EP2447370B1 (en) | 2001-09-28 | 2018-07-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| CA2715078C (en) | 2007-09-26 | 2019-07-23 | Intrexon Corporation | Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression |
| EP2288336B8 (en) | 2008-04-25 | 2017-03-22 | Northwestern University | Nanostructures suitable for sequestering cholesterol |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| KR101766408B1 (ko) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| CA2824526C (en) | 2011-01-11 | 2020-07-07 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
| AU2013374345A1 (en) | 2013-01-17 | 2015-08-06 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| US10821175B2 (en) | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
| JP7194594B2 (ja) | 2016-05-18 | 2022-12-22 | モデルナティエックス インコーポレイテッド | 免疫調節ポリペプチドをコードするｍＲＮＡの組み合わせ及びその使用 |
| MX2021003015A (es) * | 2018-09-13 | 2021-07-15 | Modernatx Inc | Polinucleotidos que codifican glucosa-6-fosfatasa para el tratamiento de la glucogenosis. |
| JP2022500444A (ja) * | 2018-09-14 | 2022-01-04 | モダーナティエックス・インコーポレイテッドModernaTX, Inc. | クリグラー−ナジャー症候群の治療のためのウリジン二リン酸グリコシルトランスフェラーゼ１ファミリー、ポリペプチドａ１をコードするポリヌクレオチド |
| AU2021205337A1 (en) * | 2020-01-10 | 2022-07-21 | Modernatx, Inc. | Methods of making tolerogenic dendritic cells |
| EP4096720A2 (en) * | 2020-01-30 | 2022-12-07 | ModernaTX, Inc. | Mrnas encoding metabolic reprogramming polypeptides and uses thereof |
| CN118369111A (zh) * | 2021-12-08 | 2024-07-19 | 摩登纳特斯有限公司 | 单纯疱疹病毒mRNA疫苗 |
-
2021
- 2021-06-23 EP EP21748991.3A patent/EP4168556A2/en active Pending
- 2021-06-23 IL IL299196A patent/IL299196A/en unknown
- 2021-06-23 KR KR1020237000782A patent/KR20230042005A/ko not_active Withdrawn
- 2021-06-23 JP JP2022579691A patent/JP2023531511A/ja active Pending
- 2021-06-23 CA CA3187261A patent/CA3187261A1/en active Pending
- 2021-06-23 AU AU2021297248A patent/AU2021297248A1/en not_active Abandoned
- 2021-06-23 US US18/012,094 patent/US20230242908A1/en active Pending
- 2021-06-23 MX MX2022016550A patent/MX2022016550A/es unknown
- 2021-06-23 CN CN202180051902.6A patent/CN116194151A/zh active Pending
- 2021-06-23 WO PCT/US2021/038780 patent/WO2021262909A2/en not_active Ceased
- 2021-06-23 BR BR112022025991A patent/BR112022025991A2/pt not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023531511A5 (https=) | ||
| DE112021000012C9 (de) | Coronavirus-Vakzine | |
| US11241493B2 (en) | Coronavirus vaccine | |
| US11471525B2 (en) | Coronavirus vaccine | |
| US6727355B2 (en) | Pharmaceutical composition for treatment of Duchenne muscular dystrophy | |
| JP2024514183A (ja) | エプスタイン－バーウイルスｍＲＮＡワクチン | |
| CN115175698A (zh) | 冠状病毒rna疫苗 | |
| JP2022552371A5 (https=) | ||
| JP2023526059A5 (https=) | ||
| CN116617382B (zh) | 新型冠状病毒疫苗及其制备方法和应用 | |
| WO2023137550A1 (en) | Compositions and methods for the prevention and/or treatment of covid-19 | |
| CN116615233A (zh) | 用于使生物分子在受试者中表达的系统和方法 | |
| WO2024055272A1 (zh) | 能高效表达目的基因的mRNA载体系统、其构建及应用 | |
| DE202023106198U1 (de) | Impfstoff auf Nukleinsäurebasis | |
| CN120813371A (zh) | 用于在衣原体病的治疗中使用的组合物 | |
| WO2023050003A1 (en) | Compositions and methods for the prevention and/or treatment of covid-19 | |
| KR20260042173A (ko) | 알파-1 안티트립신 결핍증을 위한 치료 | |
| KR20250099770A (ko) | 코로나바이러스에 대한 백신 | |
| US20230084012A1 (en) | Vaccine for use against coronavirus and variants thereof | |
| US20260027197A1 (en) | Vaccine antigens and use thereof | |
| WO2024073848A1 (en) | Compositions and methods for the prevention and/or treatment of covid-19 | |
| WO2026055516A1 (en) | Method for prevention and treatment of viral disease | |
| HK40090393B (zh) | 新型冠状病毒疫苗及其制备方法和应用 | |
| WO2024156053A1 (en) | Nucleic acid vaccines for varicella-zoster virus (vzv) | |
| WO2024199419A1 (zh) | 一种抗新冠病毒的蛋白或mRNA疫苗及其制备方法和应用 |